Author:
Puerta-García E.,Urbano-Pérez D.,Carrasco-Campos M.I.,Pérez-Ramírez C.,Segura-Pérez A.,Calleja-Hernández ,Cañadas-Garre M.
Funder
Instituto de Salud Carlos III
European Regional Development Fund
Reference36 articles.
1. Cáncer de colon (PDQ®)-Versión para profesionales de salud, 7 Marzo,2017
2. AEMPS, Ficha Técnica Xeloda®, (n.d.).
3. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients;Ruzzo;Br. J. Canc.,2017
4. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan;Falvella;Br. J. Clin. Pharmacol.,2015
5. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients;Kristensen;J. Int. Med. Res.,2010
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献